TKM, the biopharmaceutical affiliate of Kolmar Holdings Korea, has changed its name to "HK Bio Innovation."
TKM, which started in 2002 as the bio business unit of the TS Corp., is a biopharmaceutical company specializing in EPO (Erythropoietin) that is used as an anemia treatment for chronic renal failure patients and was acquired by Kolmar Holdings Korea in July last year.
TKM's new name, HK Bio Innovation, has the will to become a global biopharmaceutical company by developing innovative products, a Kolmar Holdings Korea official said.
Based on the know-how in bio-medicine research, development and production that has been accumulated for about 20 years, HK Bio Innovation plans to expand its scope to not only CDMO (Contract Development & Manufacturing Organization) but also to the development of advanced bio-medicine through active open innovation.
HK Bio Innovation, which was acquired by Kolmar Holdings Korea in July last year, is a biopharmaceutical company specializing in red blood cell-producing factors (EPO) that are used as anemia treatment for chronic renal failure patients.
Based on the know-how of bio-medicine research, development, and production that has been accumulated for about 20 years, HK Bio Innovation is planning to expand its scope to not only consignment development (CDMO) but also advanced bio-medicine development through active open innovation.
Kolmar Korea group, a global company specializing in research and development of cosmetics, pharmaceuticals and health functional foods, acquired HK Inno N (formerly CJ Healthcare) in 2018 and has been strengthening its pharmaceutical bio business by investing in a new sap plant and acquiring TKM last year.
